BIOGY (BioGaia AB) Receivables Turnover: (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BIOGY BioGaia AB BIOGY
99 GF Score
Price $12.45
GF Value $11.90
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is BioGaia AB Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. BioGaia AB's Revenue for the three months ended in Jun. 2026 was $47.1 Mil. BioGaia AB's average Accounts Receivable for the three months ended in Jun. 2026 was $0.0 Mil.

BioGaia AB  (OTCPK:BIOGY) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

BioGaia AB Receivables Turnover Related Terms

BioGaia AB Receivables Turnover Historical Data

* Premium members only.

The historical data trend for BioGaia AB's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioGaia AB Receivables Turnover Chart

BioGaia AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Receivables Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.29 8.51 10.60 9.72 7.72

BioGaia AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Receivables Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 2.00 1.74 -

BIOGY vs ZTS: Receivables Turnover Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioGaia AB Receivables Turnover vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where BioGaia AB's Receivables Turnover falls into.


BIOGY
99GF Score
BioGaia AB BIOGY
Receivables Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioGaia AB Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

BioGaia AB's Receivables Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Receivables Turnover (A: Dec. 2025 )
=Revenue / Average Accounts Receivable
=Revenue (A: Dec. 2025 ) / ((Accounts Receivable (A: Dec. 2024 ) + Accounts Receivable (A: Dec. 2025 )) / count )
=156.83574834074 / ((17.175283390275 + 23.448605024515) / 2 )
=156.83574834074 / 20.311944207395
=7.72

BioGaia AB's Receivables Turnover for the quarter that ended in Jun. 2026 is calculated as

Receivables Turnover (Q: Jun. 2026 )
=Revenue / Average Accounts Receivable
=Revenue (Q: Jun. 2026 ) / ((Accounts Receivable (Q: Mar. 2026 ) + Accounts Receivable (Q: Jun. 2026 )) / count )
=47.078323333761 / (( + ) / 1 )
=47.078323333761 / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is BioGaia AB (BIOGY) Overvalued in 2026?

Based on GuruFocus' analysis, BioGaia AB stock appears to be overvalued. The current stock price of $12.45 is trading 4.6% above its estimated GF Value™ of $11.90. GuruFocus considers BioGaia AB to be Fairly Valued.

Key valuation signals for BIOGY:

  • Receivables Turnover:
  • GF Value™: $11.90 vs. price of $12.45 (4.6% above fair value)
  • GF Score™: 99/100 with 1 warning sign

No single metric tells the full story. See the BIOGY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioGaia AB Business Description

Address Kungsbroplan 3A, Stockholm, SWE, SE-112 27
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
99GF Score

Get the complete analysis for BIOGY

Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.45
Price
$11.90
GF Value